



Senate Finance Committee
Senate Bill 905
Maryland Advanced Manufacturing Grant Program Fund - Established
March 5, 2026

Chair Beidle, Vice Chair Hayes, and Members of the Committee:

On behalf of the University of Maryland, College Park (UMCP), we respectfully submit this testimony in support of Senate Bill 905, establishing the Maryland Advanced Manufacturing Grant Program Fund within TEDCO.

SB905 recognizes that while Maryland is a national leader in research and discovery, we must also strengthen our capacity to commercialize, manufacture, and scale innovative technologies within our borders.

SB 905 establishes a dedicated fund within TEDCO to provide capital grants to growing Maryland companies specializing in regenerative medicine, life sciences, and other advanced manufacturing sectors. These grants would support facility upgrades, infrastructure improvements, and the acquisition of specialized equipment necessary to expand manufacturing capacity.

Advanced manufacturing is a powerful economic driver. Every dollar invested in advanced manufacturing generates an estimated \$2.64 in economic impact, and each manufacturing job supports nearly five additional jobs. By helping companies expand production in Maryland, this program strengthens our industrial base, accelerates job creation, and enhances long-term economic resilience.

For Maryland to compete nationally and globally, we must transition from being primarily a research hub to becoming a leader in commercial-scale production. Regenerative medicine, bio-manufacturing, and other advanced manufacturing sectors are highly competitive industries. Without targeted capital support, early-stage and scaling companies may struggle to build the infrastructure needed to remain in Maryland.

SB 905 directly addresses this challenge. By providing capital grants at a critical stage of growth, the program enables companies to secure equipment, upgrade facilities, and expand production capacity here in the state. This reduces the likelihood that promising Maryland firms will relocate to other states.

Maryland has already seen success in this sector. Companies such as Nature Cell, AstraZeneca, MilliporeSigma, and Lonza have made significant manufacturing investments across the state. Homegrown companies like RoosterBio and Theradaptive demonstrate how targeted support can lead to workforce expansion, revenue growth, and sustained innovation. SB 905 builds upon these successes and helps ensure that more Maryland-born companies follow similar trajectories.

For the University of Maryland, this legislation aligns closely with our strategic priorities of innovation, commercialization, and economic development. Our faculty and researchers regularly collaborate with advanced manufacturing and life science companies. Strengthening Maryland's manufacturing ecosystem enhances opportunities for faculty research, workforce training, and industry partnerships. It also reinforces the state's investment in higher education research by ensuring that discoveries made in Maryland can be manufactured and scaled in Maryland.

By accelerating advanced manufacturing capacity, SB 905 will stimulate economic growth, attract private investment, create high-wage jobs, and cultivate a ecosystem that connects researchers, entrepreneurs, and investors.

For these reasons, the University of Maryland, College Park respectfully urges a favorable report on Senate Bill 905.

Thank you for your consideration.

jmlewis@umd.edu